All In Biotech

Drug Trial Radar · NCT06610071

NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique

Near-infrared Fluorescence Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose Second Window Indocyanine Green Technique: a Multicenter Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

592

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Dec 2028

Study completion Dec 30, 2030

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Peking University Third Hospital; Chinese PLA General Hospital; Peking University International Hospital
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study will evaluate how near-infrared fluorescence (NIRF) imaging with low-dose second window indocyanine green (ICG) can assist in the radical resection and pathologic diagnosis of malignant soft tissue sarcoma, such as dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC) during surgery.

Conditions

  • Dermatofibrosarcoma Protuberans (DFSP)
  • Skin Squamous Cell Carcinoma

Interventions

  • ICG administrationDrug

    The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.

  • ICG administrationDrug

    The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.

  • ICG administrationDrug

    The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group

  • ICG administrationDrug

    The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-year local recurrence rateTime frame: up to 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.